CLINICAL RELEVANCE: DRUG–DRUG INTERACTION,PHARMACOKINETICS,PHARMACODYNAMICS, AND TOXICITY - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 864

724. Drummer OH, Thompson J, Hooper R, Jarrott B. 1985. Effect of probenecid on the
disposition of captopril and captopril dimer in the rat. Biochem Pharmacol 34: 3347-
3351.
725. Sinhvi SM, Duchin KL, Willard DA, McKinstry DN, Migdalof BH. 1982. Renal
handling of captopril: effect of probenecid. Clin Pharmacol Ther 32: 182-189.
726. Zarychanski R, Wlodarczyk K, Ariano R, Bow E. 2006. Pharmacokinetic interac-
tion between methotrexate and piperacillin/tazobactam resulting in prolonged toxic
concentrations of methotrexate. J Antimicrob Chemother 58: 228-230.
727. Titier K, Lagrange F, Pehourq F, Edno-Mcheid L, Moore N, Molimard M. 2002.
Pharmacokinetic interaction between high-dose methotrexate and oxacillin. Ther Drug
Monit 24: 570-572.
728. Ronchera CL, Hernandez T, Peris JE, Torres F, Granero L, Jimenez NV, Pla JM. 1993.
Pharmacokinetic interaction between high-dose methotrexate and amoxycillin. Ther
Drug Monit 15: 375-379.
729. Iven H, Brasch H. 1986. Influence of the antibiotics piperacillin, doxycycline, and
tobramycin on the pharmacokinetics of methotrexate in rabbits. Cancer Chemother
Pharmacol 17: 218-222.
730. Cundy KC. 1999. Clinical pharmacokinetics of the antiviral nucleotide analogues
cidofovir and adefovir. Clin Pharmacokinet 36: 127-143.
731. Servais A, Lechat P, Zahr N, Urien S, Aymard G, Jaudon MC, Deray G, Isnard Bagnis
C. 2006. Tubular transporters and clearance of adefovir. Eur J Pharmacol 540: 168-
174.
732. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH. 1999. The antiviral
nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal
organic anion transporter 1. Mol Pharmacol 56: 570-580.
733. Gimeno MJ, Martinez M, Granero L, Torres-Molina F, Peris JE. 1996. Influence of
probenecid on the renal excretion mechanisms of cefadroxil. Drug Metab Dispos 24:
270-272.
734. Spina SP, Dillon EC Jr. 2003. Effect of chronic probenecid therapy on cefazolin serum
concentrations. Ann Pharmacother 37: 621-624.
735. Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD. 1997. Comparison of
dose doubling with probenecid for sustaining serum cefuroxime levels. J Antimicrob
Chemother 40: 903-906.
736. Fletcher CV, Henry WK, Noormohamed SE, Rhame FS, Balfour HH Jr. 1995. The effect
of cimetidine and ranitidine administration with zidovudine. Pharmacotherapy 15: 701-
708.
737. Aiba T, Sakurai Y, Tsukada S, Koizumi T. 1995. Effects of probenecid and cimetidine
on the renal excretion of 3 -azido-3 -deoxythymidine in rats. J Pharmacol Exp Ther 272:
94-99.
738. de Miranda P, Good SS, Yarchoan R, Thomas RV, Blum MR, Myers CE. 1989. Alteration
of zidovudine pharmacokinetics by probenecid in patiets with AIDS and AIDS-related
complex. Clin Pharmacol Ther 46: 494-500.
739. Hedaya MA, Elmquist WF, Sawchuk RJ. 1990. Probenecid inhibits the metabolic and
renal clearances of zidovudine (AZT) in human volunteers. Pharm Res 7: 411-417.
740. Fenster PE, White NW Jr, Hanson CD. 1985. Pharmacokinetic evaluation of the
digoxin-amiodarone interaction. J Am Coll Cardiol 5: 108-112.